J. Patel

Development of Aqueous Based Formulation of Docetaxel: Safety andPharmacokinetics in Patients with Advanced Solid Tumors

Ey, S. Sheikh, Shoukath M. Ali, 2015 .

Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC.

C. Azzoli, P. Zatloukal, G. Weems, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

J. Kolesar, J. Schiller, J. Brahmer, 2014, European journal of cancer.

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients

A. Leo, M. Toi, L. Biganzoli, 2017, Asia-Pacific journal of clinical oncology.

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

P. Jänne, J. Neal, Gregory Riely, 2020 .

Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib.

A. Argiris, J. Coon, V. Villaflor, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.